KRAS Inhibitor Resistance in MET -Amplified KRAS G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

Suzuki, Shinichiro; Yonesaka, Kimio; Teramura, Takeshi; Takehara, Toshiyuki; Kato, Ryoji; Sakai, Hitomi; Haratani, Koji; Tanizaki, Junko; Kawakami, Hisato; Hayashi, Hidetoshi; Sakai, Kazuko; Nishio, Kazuto; Nakagawa, Kazuhiko

doi:10.1158/1078-0432.ccr-21-0856

KRAS Inhibitor Resistance in MET -Amplified KRAS G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

Purpose: Treatment with KRASG12C inhibitors such as sotorasib can produce substantial regression of tumors in some patients with non–small cell lung cancer (NSCLC). These patients require alternative treatment after acquiring resistance to the inhibitor. The mechanisms underlying this acquired re…